Brainsway Ltd. (BWAY), the Israeli medtech company pioneering Deep Transcranial Magnetic Stimulation (Deep TMS) for treating tough mental health conditions like depression and OCD, is finally showing signs of a long-awaited turnaround. After years of grinding through losses and a volatile stock price battered by COVID disruptions and regulatory hurdles, the company flipped to profitability in 2024 while ramping up revenue. With analysts projecting explosive growth ahead and a recent stock close that’s already pricing in some optimism, everyday investors might wonder: is this a breakout story or just another biotech rollercoaster? Let’s unpack the numbers, spot the trends, and see how the stock stacks up against the fundamentals.
Revenue Ramp-Up and Operational Efficiency
Revenue has been the bright spot for Brainsway, climbing steadily from about $11 million in 2016 to $41 million in 2024—a whopping 270% increase over eight years. That’s no small feat for a company with roughly 100-134 employees, as revenue per employee soared from negligible levels early on to $342,000 in 2024, up 13% from 2023’s $300,000. This metric is crucial because it highlights productivity; in medtech, where R&D and regulatory approvals eat up resources, efficient scaling without massive headcount bloat signals smart management.
Looking ahead, analysts forecast revenue jumping to $52 million in 2025 (26% growth), $65 million in 2026 (25% more), and $79 million in 2027 (21% growth). These projections correlate tightly with historical trends—revenue grew 19% annually from 2019-2024 despite pandemic headwinds. Key drivers? Expansions in U.S. installations of their TMS systems, bolstered by FDA clearances: the big one was 2020’s approval for OCD treatment, which opened new markets amid rising mental health awareness post-COVID. More recently, 2023’s nod for anxious depression treatment likely fueled the 2024 surge from $32 million to $41 million (29% jump).
Gross margins have held steady around 74-78%, a solid range for hardware-heavy medtech where manufacturing costs matter. This stability means pricing power on their systems and services isn’t eroding, even as they scale.
Profitability Pivot: From Red Ink to Black
Here’s where the story gets exciting—Brainsway was a cash-burning machine for years, with net losses peaking at $13.3 million in 2022. But 2024 delivered $2.9 million in net income, reversing 2023’s $4.2 million loss (169% swing). Earnings per share (EPS) flipped from -0.26 to +0.18, and EBT margin turned positive at 8.4%. Why does this matter? Profitability metrics like ROE (return on equity) went from -9.7% in 2023 to +5.6% in 2024, showing shareholders’ capital is finally generating returns instead of evaporating.
Analyst forecasts paint an even rosier picture: net income at $6.6 million in 2025 (126% growth), $10.6 million in 2026 (61% more), and $12.5 million in 2027 (18% up). EBT margin holds at breakeven or better, implying sustained ops discipline. Free cash flow per share, a key gauge of real cash generation after capex, rocketed to +0.38 in 2024 from -0.07 prior—a 644% improvement. With capex stabilizing (projected at $1 million annually), this could fund growth without dilution headaches, though shares outstanding ballooned to 39 million projected from 17 million in 2024 due to past raises.
This turnaround correlates with post-COVID recovery: mental health demand spiked, and Brainsway’s non-invasive TMS filled a gap left by shortages in traditional therapies. No major debt issues—total debt dwindled to near-zero by 2023—keeps balance sheet clean, with shareholders’ equity up to $62 million in 2024 (50% from 2023).
Stock Price Journey: Volatility to Value?
The stock’s wild ride mirrors the fundamentals. Historical lows and highs tell the tale: in 2019 (pre-OCD approval), it traded 8 to 12; 2020 COVID crash sent lows to 5 but highs held 12; by 2023, desperation lows hit 1.38 amid losses. Yet 2024 saw lows at 4.61 and highs at 11—still muted despite profitability. Fast-forward to the most recent close, and it’s surged dramatically, now trading about 130% above 2024 highs and over 500% from 2023 lows.
This decoupling from past fundamentals is telling. While revenue grew, the stock languished (PS ratio dipped to 1.4 in 2022 from 4-5 earlier), reflecting biotech skepticism. Now, with profits, the PS ratio sits around 4, PB around 2.6—reasonable for growth medtech. PE was lofty at 55 in 2024 but could compress with EPS gains. EV/Sales projects to 5.8-8.8 forward, aligning with revenue acceleration. Historically, stock lagged revenue (e.g., 2022 revenue down 8% but stock tanked harder), but recent momentum suggests the market’s catching up to the profitability shift.
Valuation and Analyst Optimism
Analysts are bullish: the consensus price target implies roughly 30% upside from recent levels, with the high end at 30% and low at -17% downside. This isn’t pie-in-the-sky; it tracks projected revenue tripling from 2024 levels by 2027 and EPS potentially doubling annually. EV/FCF improved to 14.7 in 2024 from negative territory, underscoring cash flow maturation.
Compare to peers: Brainsway’s EV/Sales (2.3 now, rising forward) is below many TMS/neurotech plays, yet growth outpaces. If they hit forecasts, ROA could hit low-single digits by 2027 from 3.7% in 2024—attractive for a small-cap scaler.
Insider Activity: Quiet on All Fronts
No buys or sells from insiders over the past year (March 2025 through Feb 2026 data)—a neutral signal. In a hot stock, you’d expect some profit-taking, but zero activity might reflect confidence or lockups post-fundraises. Not alarming, but watch for alignment as shares dilute less going forward.
Risks, Catalysts, and Investor Takeaway
Challenges linger: heavy R&D reliance (depreciation steady at $1.5-2.8 million yearly) and competition from Neuronetics or MagVenture could pressure margins. Capex ticked up to $3.8 million in 2024 (59% rise), likely for manufacturing scale, but FCF covered it. Geopolitical risks in Israel add volatility—recall 2023-2024 escalations impacting tech sentiment.
Catalysts? Pipeline wins like potential smoking cessation approval (rumored post-2023) or international expansions. With working capital at $64 million (up 41% YoY), they’ve got dry powder.
Bottom line for retail investors: Brainsway’s shift from lossmaker to growth engine justifies the recent pop, and analyst targets suggest more room to run—25-30% potential if execution holds. It’s riskier than blue-chips, but for those eyeing medtech with real revenue behind the hype, BWAY merits a spot on the watchlist. Pair it with broader mental health trends, and the upside could shine brighter than those TMS coils.
(Word count: 1,128)